Biotech manufacturer of short-acting psychedelics for therapeutic use Small Pharma Inc. DMTTF was granted a patent by the Canadian Intellectual Property Office from July 19, 2022, which protects the composition of matter of certain deuterated DMT analogs including the active ingredient in the drug candidate SPL028.

The patent is Small Pharma’s most recent existing patents for SPL028, particularly those of the UK and Europe, a win that appears to bolster the company’s asset protection in international markets.

Regarding her portfolioSmall Pharma has recently received a problem notification by the United States Patent and Trademark Office (USPTO) stating that the relevant patent application for novel injectable formulations of DMT-based compounds, including the active ingredients, in SPL026 and SPL028will be granted on August 9, 2022.

The company has also shared its Financial and operating results for the year ended February 28, 2022.

At the re-announcement Managing Director George Tziras commented, “As we prepare to enter the clinic with SPL028, this additional protection strengthens our development strategy around one of our key pipeline compounds. We are pleased that the Canadian Patent Office is recognizing our efforts to develop novel and differentiated medicines, which validates Small Pharma’s ability to mature our portfolio in multiple jurisdictions.”

Photo courtesy of Unsplash.